Evidence map›Paper›PMID 30870480›Full record

ArticlePloS one2019

Role of peroxiredoxin of the AhpC/TSA family in antioxidant defense mechanisms of Francisella tularensis.

Arwa Alharbi, Seham M Rabadi, Maha Alqahtani, Dina Marghani, Madeline Worden, Zhuo Ma, Meenakshi Malik, Chandra Shekhar Bakshi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Diverse roles of low-molecular weight thiol GSH inCurrent research in microbial sciences · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Control ofMicroorganisms · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Arwa AlharbiDepartment of Microbiology and Immunology, New York Medical College, Valhalla, New York, United States of America.
Seham M RabadiDepartment of Microbiology and Immunology, New York Medical College, Valhalla, New York, United States of America.
Maha AlqahtaniDepartment of Microbiology and Immunology, New York Medical College, Valhalla, New York, United States of America.
Dina MarghaniDepartment of Microbiology and Immunology, New York Medical College, Valhalla, New York, United States of America.
Madeline WordenDepartment of Basic and Clinical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, United States of America.
Zhuo MaDepartment of Basic and Clinical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, United States of America.
Meenakshi MalikDepartment of Basic and Clinical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, United States of America.
Chandra Shekhar BakshiDepartment of Microbiology and Immunology, New York Medical College, Valhalla, New York, United States of America.ORCID 0000-0001-5459-3225
New York Medical College · USAlbany College of Pharmacy and Health Sciences · US

Funding

TLR2/NLR Signal Regulation of Protective Immunity to F. TularensisP01AI056320 · NIAID · ALBANY MEDICAL COLLEGE · PI METZGER, DENNIS W · 2003 to 2016
$22.9M
Repression of Inflammasome by Francisella tularensisR15AI107698 · NIAID · ALBANY COLLEGE OF PHARMACY · PI MALIK, MEENAKSHI · 2013 to 2024
$1.9M
Modulation of host innate immune response by Francisella tularensisR56AI101109 · NIAID · NEW YORK MEDICAL COLLEGE · PI BAKSHI, CHANDRA SHEKHAR · 2013 to 2013
$390k
NIAID NIH HHS P01 AI056320NIAID NIH HHS R15 AI107698NIAID NIH HHS R56 AI101109
6 · The paper itself

Abstract

Francisella tularensis is a Gram-negative, facultative intracellular pathogen and the causative agent of a lethal human disease known as tularemia. Due to its extremely high virulence and potential to be used as a bioterror agent, F. tularensis is classified by the CDC as a Category A Select Agent. As an intracellular pathogen, F. tularensis during its intracellular residence encounters a number of oxidative and nitrosative stresses. The roles of the primary antioxidant enzymes SodB, SodC and KatG in oxidative stress resistance and virulence of F. tularensis live vaccine strain (LVS) have been characterized in previous studies. However, very fragmentary information is available regarding the role of peroxiredoxin of the AhpC/TSA family (annotated as AhpC) of F. tularensis SchuS4; whereas the role of AhpC of F. tularensis LVS in tularemia pathogenesis is not known. This study was undertaken to exhaustively investigate the role of AhpC in oxidative stress resistance of F. tularensis LVS and SchuS4. We report that AhpC of F. tularensis LVS confers resistance against a wide range of reactive oxygen and nitrogen species, and serves as a virulence factor. In highly virulent F. tularensis SchuS4 strain, AhpC serves as a key antioxidant enzyme and contributes to its robust oxidative and nitrosative stress resistance, and intramacrophage survival. We also demonstrate that there is functional redundancy among primary antioxidant enzymes AhpC, SodC, and KatG of F. tularensis SchuS4. Collectively, this study highlights the differences in antioxidant defense mechanisms of F. tularensis LVS and SchuS4.

Indexed as

Oxidative StressAnimalsAntioxidantsBacterial ProteinsBacterial VaccinesFrancisella tularensisGenetic Complementation TestMacrophagesMiceMice, Inbred C57BLPeroxiredoxinsRAW 264.7 CellsSuperoxide DismutaseTularemiaVaccines, AttenuatedVirulenceAntioxidantsBacterial ProteinsBacterial VaccinesPeroxiredoxinsSuperoxide DismutaseVaccines, Attenuated

Identifiers

PMID30870480
PMCPMC6417708
OpenAlexW2922410370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.